Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Epithelioid sarcoma, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No approved targeted therapy since the March 2026 withdrawal: next-generation PRC2 inhibitors such as rinzimetostat (EED) are being tested in other cancers, and whether one can be brought to epithelioid sarcoma is open.
The EZH-301 doxorubicin combination and immunotherapy combinations were still recruiting when tazemetostat was withdrawn; their read-outs would show whether the EZH2 axis is worth revisiting.
Checkpoint inhibition has a signal but no approval: talimogene laherparepvec with pembrolizumab gave a 35% objective response rate across 20 patients with advanced sarcoma of mixed histology (Kelly and colleagues, JAMA Oncol 2020), and the AcSe rare-sarcoma basket gave 6.2% at week 12 across 97 patients (Blay and colleagues, Lancet Oncol 2023).
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Late diagnosis of distal lesions mistaken for warts or granulomas.
Proximal-type disease remains chemoresistant and rapidly progressive.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
Ipsen withdraws tazemetostat in all indications on 9 March 2026 after the SYMPHONY-1 data monitoring committee flagged secondary haematologic malignancies (18/318 patients, 5.7%, per the FDA safety communication).
Accelerated approval, epithelioid sarcoma
Epithelioid sarcoma; relapsed FL (EZH2-mutant after 2 lines; wild-type without alternatives)
Doxorubicin with or without tazemetostat, first line (NCT04204941).
FDA, 23 January 2020, based on EZH-202 (Gounder and colleagues, Lancet Oncol 2020).